SGLT-2抑制剂和GLP-1受体激动剂的联合使用_替代终点和硬终点的潜在好处.pdf,1879 Send Orders for Reprints to reprints@benthamscience.ae Current Pharmaceutical Design, 2018, 24, 1879-1886 REVIEW ARTICLE Combination of SGLT-2 Inhibitors and GLP-1 Receptor Agoni
Combination SGLT2 inhibitor and GLP-1 receptor agonist therapy: a complementary approach to the treatment of type 2 diabetes[ J]. Postgrad Med, 2017, 129(7): 686-697. 19. Pratley RE, Cersosimo E. Use of canagliflozin in combination with and compared to incretin-based therapies in type 2...
DISCOVER研究为期3年,纳入了7613例2型糖尿病患者,接受二甲双胍联合二线降糖方案,包括二甲双胍联合磺脲类药物(40.9%)、DPP-4抑制剂(48.3%)、SGLT-2抑制剂(8.3%)或GLP-1受体激动剂。 36个月后,不同治疗方案的患者糖化血红蛋白降低幅度相似(-0.8%～-1.0%),然而,二甲双胍联合磺脲类药物组的体重减轻幅度小于其他...
Sodium-glucose co-transporter-2 inhibitors (SGLT-2i) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) are now considered as key players in the treatment of type 2 diabetes mellitus (T2DM). We aimed at providing precise effect estimates regarding the effect of their combination on ...
钠-葡萄糖协同转运蛋白2抑制剂(SGLT2i)、胰高血糖素样肽-1受体激动剂(GLP-1 RA)和非甾体盐皮质激素受体拮抗剂(ns-MRA)非奈利酮单独使用均能减少2型糖尿病和蛋白尿患者的心血管事件、慢性肾脏疾病(CKD)进展和死亡率。然而,这些药物联合治疗的终身...
[37] Eng, C., Kramer, C.K., Zinman, B., Retnakaran, R. 2014. Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis. Lancet 384:2228-2234. ...
在另一项研 双胍联合SU治疗血糖控制仍不达标的患者加用 究中,SGLT2i(单药或联合二甲双胍)治疗血糖控制 GLP‐1RA时建议适当减少SU的剂量,并加强血糖 不达标的 T2DM 患者加用度拉糖肽 1.5mg 和 监测,以减少低血糖发生风险。 0.75mg(每周1次)治疗24周后,HbA1c分别下降 研究显示,二甲双胍联合SU血糖控制不佳...
The SGLT2i and GLP-1 RAs also reduced macroalbuminuria, decreased the time for doubling of serum creatinine, and slowed the time to end-stage renal disease. In this perspective, we review the potential benefit of combination SGLT2i/GLP-1 RA therapy on metabolic-cardiovascular-renal disease in...
Combination therapy with SGLT-2 inhibitors and GLP-1 receptor agonists as FullTerms&Conditionsofaccessandusecanbefoundathttps://.tandfonline/action/journalInformation?journalCode=ipgm20PostgraduateMedicineISSN:0032-5481(Print)1941-9260(Online)Journalhomepage:https://.tandfonline/loi/ipgm20Combinationthe...
A compound having agonist activity at the GLP-1 (glucagon-like-peptide 1) and GLP-2 (glucagon-like peptide 2) receptors, and a pharmaceutical composition containing the compound or a pharmaceutically acceptable salt or solvate thereof in admixture with a pharmaceutically acceptable carrier, an excipi...